(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 76.16% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.72%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.39%.
Ac Immune Sa's revenue in 2026 is $21,616,049.On average, 6 Wall Street analysts forecast ACIU's revenue for 2026 to be $1,862,391,538, with the lowest ACIU revenue forecast at $342,769,576, and the highest ACIU revenue forecast at $2,724,148,235. On average, 6 Wall Street analysts forecast ACIU's revenue for 2027 to be $9,244,400,851, with the lowest ACIU revenue forecast at $0, and the highest ACIU revenue forecast at $28,043,211,131.
In 2028, ACIU is forecast to generate $10,916,941,386 in revenue, with the lowest revenue forecast at $6,381,272,728 and the highest revenue forecast at $18,256,625,931.